Company: MYSZ
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000990
Chunk: 620

Company: My Size, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 620
---
 Branitzky served as an advisory board member of ciValue. Mr. Branitzky received
a B.S. from the Hebrew University of Jerusalem and an MBA in International Marketing from Tel Aviv University. We believe that Mr. Branitzky
is qualified to serve as a member of our board of directors because of his more than 20 years of experience in managing the sales of
hi-tech solutions to retailers across the globe.

Roy Golan, has served as a member of our board of directors since March 2025. He acts
as a financial advisor since July 2024 and currently serves as a director of Neurosense Therapeutics Ltd. (NASDAQ: NRSN), a Nasdaq listed
company developing treatments for severe neurodegenerative diseases, since July 2024. Mr. Golan previously served as the Chief Financial
Officer of Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, from its merger with BioSight Ltd., a private
pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, in October 2023 until June 2024.
From 2019 to 2023, Mr. Golan served as Executive VP and Chief Financial Officer of BioSight Ltd. From 2018 to 2019, Mr. Golan served as
President and Chief Financial Officer of Exalenz Bioscience Ltd. (TASE: EXEN), a Tel Aviv Stock Exchange listed global, commercial-stage
diagnostics company which developed its BreathID® technology platform to improve patient care by providing breath-based tests in the
fields of gastroenterology and hepatology and was later acquired by Meridian Bioscience, Inc. (NASDAQ: VIVO). From 2015 to 2018, Mr. Golan
served as the Chief Financial Officer of NeuroDerm (NASDAQ: NDRM), a Nasdaq listed clinical-stage pharmaceutical company developing next-generation
drug-device combinations for central nervous system disorders, through its initial public offering until its acquisition by Mitsubishi
Tanabe Pharma Group Company, and prior thereto he served as their VP Finance. Mr. Golan holds an LLM from Bar Ilan University as well
as a BA from The College of Management in Rishon LeZion and is also a licensed CPA. We believe that Mr. Golan is qualified to serve as a member of our board
of directors because of his vast finance experience and public company management and administration